
BioAge Labs Stock Plummets Nearly 60% on Negative Read-Through From Novo Nordisk Trial
Shares of the biotechnology company plunged after a failed Phase 3 trial by Novo Nordisk for a similar drug cast significant doubt on the scientific hypothesis underpinning BioAge's lead cardiovascular candidate.







